The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidin-4-amine ID: ALA3728003
PubChem CID: 66836007
Max Phase: Preclinical
Molecular Formula: C17H15N5O2S3
Molecular Weight: 417.54
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: CCc1nnc(Nc2ncnc3scc(-c4cccc(S(C)(=O)=O)c4)c23)s1
Standard InChI: InChI=1S/C17H15N5O2S3/c1-3-13-21-22-17(26-13)20-15-14-12(8-25-16(14)19-9-18-15)10-5-4-6-11(7-10)27(2,23)24/h4-9H,3H2,1-2H3,(H,18,19,20,22)
Standard InChI Key: LYHRNYVRMUSNPP-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 30 0 0 0 0 0 0 0 0999 V2000
-0.3026 6.2126 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.8855 6.3807 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
1.3336 7.4939 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 0.7475 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 -0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 -1.5132 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 1.5132 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2917 0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2917 -0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 -1.2033 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
2.5889 0.0182 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 1.2033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1749 2.6315 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2517 3.8078 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8114 5.1995 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2965 5.4106 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2218 4.2301 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6621 2.8384 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9971 3.0138 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.2935 3.7700 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4279 5.2511 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
-3.8944 5.5664 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.6474 4.2692 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.6464 3.1521 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.1457 7.3255 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.5034 6.9353 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.6967 7.0618 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
4 5 2 0
5 6 1 0
6 9 2 0
8 7 2 0
7 4 1 0
8 9 1 0
9 10 1 0
10 11 1 0
11 12 2 0
12 8 1 0
13 14 2 0
14 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 13 1 0
12 13 1 0
7 19 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 2 0
23 24 1 0
24 20 2 0
15 2 1 0
2 25 1 0
22 26 1 0
26 27 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 417.54Molecular Weight (Monoisotopic): 417.0388AlogP: 3.92#Rotatable Bonds: 5Polar Surface Area: 97.73Molecular Species: ACIDHBA: 9HBD: 1#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 5.95CX Basic pKa: 2.58CX LogP: 3.10CX LogD: 1.86Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.53Np Likeness Score: -2.57
References 1. (2012) Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders, 2. Klaeger, Susan S and 47 more authors. 2017-12-01 The target landscape of clinical kinase drugs. [PMID:29191878 ]